Standout Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced soli... 2018 2026 2020 2023 440
  1. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study (2018)
    Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology

Immediate Impact

2 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

The role and regulation of integrins in cell migration and invasion
2024 Standout
Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
3 intermediate papers

Works of Mark Woodruff being referenced

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
2018 Standout

Author Peers

Author Last Decade Papers Cites
Mark Woodruff 79 339 1 117 114 10 532
Silvana Compasso 49 160 2 103 90 10 483
F. Moritz 22 285 6 86 135 16 512
Nathalie Voorzanger‐Rousselot 49 293 5 274 30 13 534
Taren Johnston 30 262 1 117 94 9 633
Justine Hollyer 65 307 6 196 37 9 644
T. Megha 21 156 3 212 186 16 496
Francine E. Carrick 63 307 2 134 20 10 600
Yoon Hee Kang 26 257 1 137 29 14 529
Nicole Kelbick 18 157 1 256 92 9 511
Elliot B. Sambol 114 221 7 192 83 14 607

All Works

Loading papers...

Rankless by CCL
2026